SC Engineering's Subsidiary Cellontech Signs Supply Contract for 'Katizol' in Vietnam

Cartizol, an intra-articular injection by Cellontec, a subsidiary of SCN Engineering, has successfully entered the rapidly aging Vietnamese market.

Cellontec, a regenerative medicine specialized bio company, announced on the 23rd that it signed an exclusive sales supply contract for Cartizol Extra in Vietnam with Khang Lam, a Vietnamese medical device distribution specialist company. Cellontec is guaranteed a minimum order quantity (MOQ) worth 9.5 billion KRW over five years from Khang Lam.

Cartizol is the first collagen intra-articular injection developed domestically by Cellontec. Among the four treatment options developed, Cartizol Extra is a product that can be administered up to twice within six months. Last year, Cellontec also signed an exclusive supply contract for Cartizol Extra with LG Chem.

Khang Lam has a distribution network of over 1,000 hospitals and clinics in Vietnam. Based on its solid local distribution network, it is responsible for distributing the German-made hyaluronic acid (HA) intra-articular injection, which currently holds the second-largest market share in the Vietnamese intra-articular injection market.

A Cellontec official said, “Cartizol, which has abundant clinical data, meets the conditions for rapid entry into the Vietnamese market, and we expect significant overseas sales to begin as early as the second half of next year. Khang Lam is expected to demonstrate steep sales growth in the rapidly aging Vietnamese market by strengthening marketing through Cartizol’s excellent therapeutic effects and synergy with existing products.”

He added, “We plan to continuously expand domestic and international sales growth not only in the field of joint cartilage regenerative medicine centered on Cartizol but also in the beauty and plastic surgery field centered on Terapil.”

Recently, Cellontec has been focusing on expanding domestic and international sales channels for its main products. Last month, it signed an exclusive sales supply contract for the collagen filler Terapil with the aesthetic business subsidiary of China’s Sahuan Pharmaceutical, laying the foundation for entry into the 55.5 billion yuan (approximately 10 trillion KRW) Chinese medical aesthetic injection market.

This content was produced with the assistance of AI translation services.